Letters to the Editor
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Aug 27, 2020; 12(8): 525-532
Published online Aug 27, 2020. doi: 10.4254/wjh.v12.i8.525
“Six-and-twelve” score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort
Xavier Adhoute, Guillaume Pénaranda, Jean-Luc Raoul, Jean-Pierre Bronowicki, Rodolphe Anty, Marc Bourlière
Xavier Adhoute, Marc Bourlière, Department of Gastroenterology and Hepatology, Hôpital Saint-Joseph, Marseille 13008, France
Guillaume Pénaranda, AlphaBio Laboratory, Marseille 13003, France
Jean-Luc Raoul, Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes 44805, France
Jean-Pierre Bronowicki, Department of Gastroenterology and Hepatology, Centre Hospitalo-Universitaire de, Nancy 54511, France
Rodolphe Anty, Department of Gastroenterology and Hepatology, Hôpital Universitaire de l’Archet, Nice 06200, France
Author contributions: Adhoute X, Raoul J, Bronowicki J and Bourlière M are physicians in charge of the patients; Adhoute X and Bronowicki J collected the data and Pénaranda G proceeded to statistical analysis; Adhoute X, Bronowicki J and Anty R wrote the manuscript.
Conflict-of-interest statement: The authors have no potential conflict of interest relevant to this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Adhoute Xavier, MD, Doctor, Department of Gastroenterology and Hepatology, Hôpital Saint-Joseph, 26 Bd de Louvain, Marseille 13008 France. adhoute.xavier@neuf.fr
Received: April 13, 2020
Peer-review started: April 13, 2020
First decision: April 22, 2020
Revised: July 5, 2020
Accepted: July 19, 2020
Article in press: July 19, 2020
Published online: August 27, 2020
Core Tip

Core tip: Not all-intermediate stage hepatocellular carcinoma (HCC) benefit from transarterial chemoembolization (TACE). The recent “six-and-twelve” (6&12) score is an easy to use prognostic model that ensure a quick and appropriate patient’ selection before the first TACE in Chinese cohorts. In this multicenter French cohort of HCC, the “6&12” score can also classify survival among recommended TACE candidates with a good prognostic performance. It may help clinicians in routine clinical practice.